Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Basilea Pharmaceutica ( (CH:BSLN) ) just unveiled an update.
Basilea Pharmaceutica reported a significant financial performance in the first half of 2025, with a 36% increase in total revenue to CHF 104 million and a 160% rise in operating profit to CHF 24 million. The company achieved key milestones, including the launch of Zevtera in the US and the start of a Phase 3 study for Fosmanogepix, bolstering its market position and future growth prospects. The financial results underscore Basilea’s robust business model, enabling continued investment in its innovative clinical pipeline.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
More about Basilea Pharmaceutica
Basilea Pharmaceutica AG is a biopharmaceutical company focused on developing and marketing products to treat severe bacterial and fungal infections. The company is known for its marketed products like Cresemba and Zevtera and is actively involved in expanding its clinical pipeline with new antibiotics and antifungal agents.
Average Trading Volume: 41,332
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF633.3M
See more insights into BSLN stock on TipRanks’ Stock Analysis page.